BCL2 and breast cancer: Recently, a prolinamide-derived peptidomimetic that specifically binds to the G4 within MYC and BCL-2 promoters has been reported to exert an antiproliferative activity in breast cancer cells overexpressing both genes, in comparison to cells that overexpress either of the two as well as to ligands belonging to the same family and showing a potent and specific inhibitory effect on either MYC or BCL-2 transcription [75].